PROTACs: Mechanism and Bioavailability enhancement strategies by nanotechnology, RNA viral infections (vaccine strategy) and Prodrug development
Proteolysis Targeting Chimera (PROTACs) are a brand-new concept of therapeutics that use the ubiquitin-proteasome system for selective degradation of disease-related proteins. Like other therapeutics, PROTACs function by recruiting a protein target and a ubiquitin ligase that leads to the degradati...
Saved in:
Main Authors: | Sanaul Mustafa, Md Sabir Hussain Siddiquee |
---|---|
Format: | Article |
Language: | English |
Published: |
German Journal of Pharmaceuticals and Biomaterials
2025-01-01
|
Series: | German Journal of Pharmaceuticals and Biomaterials |
Subjects: | |
Online Access: | https://www.gjpb.de/index.php/gjpb/article/view/154 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PROTAC-based therapeutics for targeting HPV oncoproteins in head and neck cancers
by: Nobendu Mukerjee, et al.
Published: (2025-12-01) -
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01) -
A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines
by: Linghong Huang, et al.
Published: (2025-04-01) -
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01) -
N-Oxalylglycine-Conjugated Hyaluronic Acid as a Macromolecular Prodrug for Therapeutic Angiogenesis
by: Andrew H. DeMaria, et al.
Published: (2025-01-01)